CYRX — Cryoport, Inc.

Summary of Cryoport's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Cryoport reported full-year revenue of $176.2 million from continuing operations, exceeding guidance and reflecting strong performance across core markets.
• Growth:
  • Commercial Cell and Gene Therapy Revenue: Increased 29% year-over-year to $33.4 million, representing 20% of overall revenue.
  • Clinical Trial Revenue: Grew 14% year-over-year to $47.1 million.
  • Life Sciences Services Segment: Revenue increased 18% year-over-year, with BioStorage/BioServices growing 22%.
  • Gross Margin: Improved to 47%.
  • Adjusted EBITDA: Saw a $12 million year-over-year improvement, with expectations for positive adjusted EBITDA in the second half of 2026.

2. Strategic Updates and Business Highlights

• Clinical Trials: Supported a record 760 clinical trials and 20 commercial therapies globally, with a net increase of 59 trials year-over-year.
• Partnerships: Established strategic collaborations with DHL, Cardinal Health, and Parexel to enhance service offerings and market position.
• Innovations: Launched new products including integrated condition monitoring solutions and the Fusion 800 Series cryogenic freezer, aimed at expanding market opportunities.
• Global Supply Chain Centers: Continued investment in infrastructure with centers in Paris and California to support growth in cell and gene therapy.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue between $190 million and $194 million, reflecting a growth rate of approximately 9%.
• Clinical Pipeline: Anticipates 13 BLA/MAA filings and 9 new therapy approvals in 2026, with a strong pipeline of 86 Phase III and 361 Phase II trials expected to drive future revenue.

4. Bad News, Challenges, or Points of Concern

• MVE Segment Growth: Revenue growth for the MVE segment was only 7% for the year, with 2% growth in Q4, indicating potential stagnation in a key product line.
• Macro Environment Risks: Concerns about the volatile macroeconomic environment and regulatory challenges could impact future growth.
• Integration with DHL: The partnership with DHL is still in the early stages, and full benefits may take time to materialize due to the size and complexity of the organization.

5. Notable Q&A Insights

• Funding Lag: There is typically a 6-month lag between funding in biopharma and increased customer orders.
• Growth Expectations: Management expects continued strong growth in commercial therapies, with a focus on the cell and gene therapy market as a primary driver.
• Operational Efficiency: Positive adjusted EBITDA is anticipated in the second half of 2026, driven by operational improvements and strategic investments.
• Partnership Dynamics: The partnerships with Cardinal Health and Parexel are seen as crucial for enhancing service offerings and driving industry standardization.

Overall, Cryoport demonstrated solid financial performance in 2025, with strong growth in key segments and strategic initiatives aimed at positioning the company for continued success in the evolving life sciences landscape. However, challenges in specific product lines and macroeconomic uncertainties remain points of concern.